EUS-guided Biliary Drainage of First Intent With the Lumen Apposing Metal Stent vs. ERCP in the Management of Malignant Distal Biliary Obstruction (AXIOS-CPRE)
AXIOS-CPRE
1 other identifier
interventional
15
1 country
1
Brief Summary
The main objective is to compare the EUS-BD with the insertion of a LAMS vs. traditional ERCP to restore biliary patency. Although ERCP has been the primary treatment for many years, it is associated with a significant risk of procedural complications and possible stent blockage. EUS-BD has been shown to be potentially safer and is associated with a lower risk of stent blockage. We seek with our study to determine whether EUS-BD may be the most effective treatment modality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 13, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 13, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 14, 2021
CompletedFirst Submitted
Initial submission to the registry
November 4, 2021
CompletedFirst Posted
Study publicly available on registry
November 17, 2021
CompletedNovember 17, 2021
November 1, 2021
6 months
November 4, 2021
November 16, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Number of participant with stent dysfunction (obstruction or migration) requiring endoscopic, radiological or surgical intervention
12 months
Study Arms (2)
EUS guided biliary drainage
EXPERIMENTALERCP (Endoscopic Retrograde Cholangiopancreatography
ACTIVE COMPARATORInterventions
A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
Eligibility Criteria
You may qualify if:
- Radiological diagnosis (with or without pathological diagnosis) of a malignant obstruction of the borderline resectable distal bile ducts, locally advanced or unresectable distal to the hilum, at a minimum distance of 2 cm.
- Resectability based on tumor staging after axial imaging and evaluation by a physician (surgeon, oncologist and / or gastroenterologist).
- High results of the liver function test with a serum bilirubin level at least 3 times above the upper limit of normal (18.9 μmol / L)
- Dilated extrahepatic bile duct measuring at least 1.2 cm in axial imaging, ultrasound or endoscopy.
- Karnofsky index\> 30%
- ASA score \<IV
- Patient accepting the constraints of research
- Patient affiliated or beneficiary of a social security scheme
- Patient having signed an informed consent
You may not qualify if:
- \- Hilar obstruction (biliary obstruction located \<2 cm from the hilum)
- Coagulopathy and / or thrombocytopenia that cannot be corrected
- Age \<18 years old
- Liver metastases involving\> 30% of hepatic volume
- Liver cirrhosis with portal hypertension or ascites
- Biliary sphincterotomy or placement of a stent performed in the past
- Anatomy modified by surgery
- Common bile ducts measuring less than 1.2 cm will be excluded.
- Patient with clinical and radiological signs of stenosis of the gastric outlet
- Patient participating in another clinical study
- Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision
- Pregnant, breastfeeding or parturient woman
- Patient hospitalized without consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ramsay Générale de Santélead
- European Clinical Trial Experts Networkcollaborator
Study Sites (1)
Hôpital Privé des Peupliers
Paris, 75013, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 4, 2021
First Posted
November 17, 2021
Study Start
November 13, 2020
Primary Completion
May 13, 2021
Study Completion
June 14, 2021
Last Updated
November 17, 2021
Record last verified: 2021-11